Clinical markers of early nigrostriatal neurodegeneration in idiopathic rapid eye movement sleep behavior disorder

Background: Rapid eye movement sleep behavior disorder (RBD) is an early feature in alpha synucleinopathies and may precede other clinical manifestations of disease for several years. Olfactory dysfunction and mild motor abnormalities (MMAs) are highly prevalent in prodromal alpha synucleinopathies such as RBD and are suspected to be predictive neurodegenerative markers. Because both markers also are highly prevalent in the healthy elderly population, the discriminative value to detect an early neurodegenerative process is unclear. Methods: We examined 28 patients with idiopathic RBD (iRBD) without manifest neurodegenerative disease to determine diagnostic accuracy of MMAs and olfactory dysfunction in identifying patients with early nigrostriatal degeneration in transcranial sonography (TCS) and I-123-2 beta-carbomethoxy-3 beta-(4-iodophenyl)- N-(3-fluoropropyl)-nortropane single-photon emission computed tomography (I-123-FP-CIT-SPECT). Results: Sixty-three percent of our participants showed MMAs which were strongly associated with abnormal TCS and I-123-FP-CIT-SPECT findings. The discriminative value in detecting participants with early nigrostriatal degeneration was excellent (area under the receiver operating characteristic [ROC] curve, 0.84 [P <= .003] for TCS and 0.79 [P <= .066] for I-123-FP-CIT-SPECT). Olfactory dysfunction was present in 78% of iRBD participants, but it was not linked with neuroimaging abnormalities or MMAs. Olfactory dysfunction did not discriminate participants with early nigrostriatal degeneration (area under the ROC curve, 0.54 [P <= .747] for TCS and 0.31 [P <= .225] for I-123-FP-CIT-SPECT). Early RBD manifestation but no demographic (e. g., age, gender) or clinical characteristics of RBD (e. g., duration, severity of RBD) were associated with neuroimaging abnormalities in TCS and I-123-FP-CIT-SPECT. Conclusions: Unlike olfactory dysfunction, MMAs discriminate patients with early nigrostriatal degeneration in iRBD. Early RBD manifestation seems to be an additional risk factor which aggravates neurodegenerative risk. (C) 2013 Elsevier B.V. All rights reserved.